Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Trial Profile

Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs Vadadustat (Primary) ; Epoetin alfa
  • Indications Anaemia
  • Focus Therapeutic Use
  • Acronyms FO2RWARD
  • Sponsors Akebia Therapeutics
  • Most Recent Events

    • 23 Apr 2018 Status changed from active, no longer recruiting to discontinued.
    • 12 Feb 2018 According to an Akebia Therapeutics media release, the company is planning to replace the former FO2RWARD study and implement new study design which includes a broader dialysis population in addition to hyporesponders, a larger sample size and includes once-daily and three-times-weekly dosing. This new study anticipated to initiate in Q2 2018, with top-line results expected in late 2018 or early 2019. New study is designed to generate data to inform ESA-switching protocols.
    • 11 Jan 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top